PMID- 28789709
OWN - NLM
STAT- MEDLINE
DCOM- 20180426
LR  - 20181202
IS  - 1944-446X (Electronic)
IS  - 1000-467X (Print)
IS  - 1944-446X (Linking)
VI  - 36
IP  - 1
DP  - 2017 Aug 8
TI  - Comparison of efficacy, safety, and quality of life between sorafenib and 
      sunitinib as first-line therapy for Chinese patients with metastatic renal cell 
      carcinoma.
PG  - 64
LID - 10.1186/s40880-017-0230-7 [doi]
LID - 64
AB  - BACKGROUND: Sorafenib and sunitinib are widely used as first-line targeted 
      therapy for metastatic renal cell carcinoma (mRCC) in China. This study aimed to 
      compare the efficacy, safety, and quality of life (QoL) in Chinese mRCC patients 
      treated with sorafenib and sunitinib as first-line therapy. METHODS: Clinical 
      data of patients with mRCC who received sorafenib (400 mg twice daily; 4 weeks) 
      or sunitinib (50 mg twice daily; on a schedule of 4 weeks on treatment followed 
      by 2 weeks off) were retrieved. Primary outcomes were overall survival (OS), 
      progression-free survival (PFS), adverse events (AEs), and QoL (SF-36 scores), 
      and secondary outcomes were associations of clinical characteristics with QoL. 
      RESULTS: Medical records of 184 patients (110 in the sorafenib group and 74 in 
      the sunitinib group) were reviewed. PFS and OS were comparable between the 
      sorafenib and sunitinib groups (both P > 0.05). The occurrence rates of 
      leukocytopenia, thrombocytopenia, and hypothyroidism were higher in the sunitinib 
      group (36.5% vs. 10.9%, P < 0.001; 40.5% vs. 10.9%, P < 0.001; 17.6% vs. 3.6%, 
      P = 0.001), and that of diarrhea was higher in the sorafenib group (62.7% vs. 
      35.2%, P < 0.001). There was no significant difference in SF-36 scores between 
      the two groups. Multivariate analysis indicated that role-physical and bodily 
      pain scores were associated with the occurrence rate of grade 3 or 4 AEs 
      (P = 0.017 and 0.005). CONCLUSIONS: Sorafenib has comparable efficacy and lower 
      toxicity profile than sunitinib as first-line therapy for mRCC. Both agents 
      showed no significant impact on QoL of patients.
FAU - Cai, Wen
AU  - Cai W
AD  - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong 
      University, Shanghai, 200123, P. R. China.
FAU - Kong, Wen
AU  - Kong W
AD  - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong 
      University, Shanghai, 200123, P. R. China.
FAU - Dong, Baijun
AU  - Dong B
AD  - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong 
      University, Shanghai, 200123, P. R. China.
FAU - Zhang, Jin
AU  - Zhang J
AD  - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong 
      University, Shanghai, 200123, P. R. China.
FAU - Chen, Yonghui
AU  - Chen Y
AD  - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong 
      University, Shanghai, 200123, P. R. China.
FAU - Xue, Wei
AU  - Xue W
AD  - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong 
      University, Shanghai, 200123, P. R. China.
FAU - Huang, Yiran
AU  - Huang Y
AD  - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong 
      University, Shanghai, 200123, P. R. China.
FAU - Zhou, Lixin
AU  - Zhou L
AD  - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong 
      University, 160 Pujian Rd., Pudong District, Shanghai, 200127, P. R. China. 
      zhou_li_xin@hotmail.com.
FAU - Huang, Jiwei
AU  - Huang J
AD  - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong 
      University, 160 Pujian Rd., Pudong District, Shanghai, 200127, P. R. China. 
      jiweihuang@outlook.com.
LA  - eng
PT  - Journal Article
DEP - 20170808
PL  - England
TA  - Chin J Cancer
JT  - Chinese journal of cancer
JID - 101498232
RN  - 0 (Indoles)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrroles)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Renal Cell/*drug therapy/epidemiology/pathology
MH  - China
MH  - Disease-Free Survival
MH  - Drug-Related Side Effects and Adverse Reactions/classification/pathology
MH  - Female
MH  - Humans
MH  - Indoles/*administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Niacinamide/administration & dosage/adverse effects/*analogs & derivatives
MH  - Phenylurea Compounds/*administration & dosage/adverse effects
MH  - Protein Kinase Inhibitors/*administration & dosage/adverse effects
MH  - Pyrroles/*administration & dosage/adverse effects
MH  - Quality of Life
MH  - Sorafenib
MH  - Sunitinib
MH  - Treatment Outcome
PMC - PMC5547674
OTO - NOTNLM
OT  - Metastatic renal cell carcinoma
OT  - Quality of life
OT  - Sorafenib
OT  - Sunitinib
EDAT- 2017/08/10 06:00
MHDA- 2018/04/27 06:00
PMCR- 2017/08/08
CRDT- 2017/08/10 06:00
PHST- 2016/11/08 00:00 [received]
PHST- 2017/05/01 00:00 [accepted]
PHST- 2017/08/10 06:00 [entrez]
PHST- 2017/08/10 06:00 [pubmed]
PHST- 2018/04/27 06:00 [medline]
PHST- 2017/08/08 00:00 [pmc-release]
AID - 10.1186/s40880-017-0230-7 [pii]
AID - 230 [pii]
AID - 10.1186/s40880-017-0230-7 [doi]
PST - epublish
SO  - Chin J Cancer. 2017 Aug 8;36(1):64. doi: 10.1186/s40880-017-0230-7.